{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+blood+stem+cell+infusion&page=24",
    "query": {
      "intervention": "Peripheral blood stem cell infusion",
      "page": 24
    },
    "page_size": 10
  },
  "pagination": {
    "page": 24,
    "page_size": 10,
    "total_count": 553,
    "total_pages": 56,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+blood+stem+cell+infusion&page=25&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+blood+stem+cell+infusion&page=23&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T09:51:17.200Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00506948",
      "title": "Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematological Malignancies",
        "Myelodysplastic Syndrome",
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Mycophenolate Mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Thymoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 13,
      "start_date": "2006-09",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2020-09-24",
      "last_synced_at": "2026-10-15T09:51:17.200Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00506948"
    },
    {
      "nct_id": "NCT01174940",
      "title": "Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Stem Cell Leukemia of Unclear Lineage",
        "Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "extracorporeal photopheresis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2010-06",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2017-01-09",
      "last_synced_at": "2026-10-15T09:51:17.200Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01174940"
    },
    {
      "nct_id": "NCT02167958",
      "title": "Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "MDS",
        "Myelofibrosis",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Hematopoietic stem cell infusion",
          "type": "OTHER"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Rafic Farah, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 28,
      "start_date": "2015-02-11",
      "completion_date": "2019-09-21",
      "has_results": false,
      "last_update_posted_date": "2019-10-15",
      "last_synced_at": "2026-10-15T09:51:17.200Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02167958"
    },
    {
      "nct_id": "NCT02098109",
      "title": "Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "XM02 Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "Apheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Plerixafor",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2014-08-20",
      "completion_date": "2016-09-18",
      "has_results": true,
      "last_update_posted_date": "2017-07-18",
      "last_synced_at": "2026-10-15T09:51:17.200Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02098109"
    },
    {
      "nct_id": "NCT00629798",
      "title": "Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Advanced Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 64,
      "start_date": "2008-02-12",
      "completion_date": "2020-10-20",
      "has_results": true,
      "last_update_posted_date": "2021-09-24",
      "last_synced_at": "2026-10-15T09:51:17.200Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00629798"
    },
    {
      "nct_id": "NCT00574080",
      "title": "UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Interim/Maintenance Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Induction/Consolidation Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Induction/Consolidation Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Induction/Consolidation Adriamycin",
          "type": "DRUG"
        },
        {
          "name": "InductionConsolidation Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Induction/Consolidation Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Induction Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 Adriamycin",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 and 2 Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Autologous Peripheral Blood Stem Cell Transplant (ASCT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Transplant 2 Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Transplant 2 Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Transplant 2 Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Transplant 2 Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Transplant 2 Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 and 2 Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 and 2 Thalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2006-07",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2017-11-20",
      "last_synced_at": "2026-10-15T09:51:17.200Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00574080"
    },
    {
      "nct_id": "NCT00053196",
      "title": "Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma",
        "Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "G-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "allogeneic cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "allopurinol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "Up to 69 Years"
      },
      "enrollment_count": 82,
      "start_date": "2002-12",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2016-07-01",
      "last_synced_at": "2026-10-15T09:51:17.200Z",
      "location_count": 12,
      "location_summary": "La Jolla, California • Lewes, Delaware • Newark, Delaware + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Lewes",
          "state": "Delaware"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Elkton MD",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00053196"
    },
    {
      "nct_id": "NCT00499343",
      "title": "G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "Isophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Apheresis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 84,
      "start_date": "2004-01",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2013-08-02",
      "last_synced_at": "2026-10-15T09:51:17.200Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00499343"
    },
    {
      "nct_id": "NCT00152126",
      "title": "Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neuroblastoma",
        "Central Nervous System Tumors",
        "Lymphomas",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Busulfan, Melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 26,
      "start_date": "2003-08",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2009-02-13",
      "last_synced_at": "2026-10-15T09:51:17.200Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00152126"
    },
    {
      "nct_id": "NCT05207722",
      "title": "CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic HER2 Positive Gastroesophageal Junction Cancer"
      ],
      "interventions": [
        {
          "name": "CYNK-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Recombinant Human Interleukin-2",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Celularity Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1,
      "start_date": "2022-04-14",
      "completion_date": "2024-02-15",
      "has_results": false,
      "last_update_posted_date": "2024-12-12",
      "last_synced_at": "2026-10-15T09:51:17.200Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Hackensack, New Jersey",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05207722"
    }
  ]
}